Please assess the completion status of the following clinical trial:

Trial Title: Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients after roux-y-gastric bypass or biliopancreatic diversion with documented hypoglycemia, i. e. ≤ 2.5 mmol/l and hypoglycaemic symptoms.~* For subjects with reproductive potential, willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study~Exclusion Criteria:~* Signs of current infection~* Use of any investigational drug in the last four weeks prior to enrolment~* Use of any anti-diabetic drugs~* adrenal insufficiency and/or substitution with glucocorticoids~* Neutropenia (leukocyte count \< 1.5 × 109/L or absolute neutrophil count (ANC) \< 0.5 × 109/L)~* Anemia (hemoglobin \< 11 g/dL for males, \< 10 g/dL for females)~* Clinically significant kidney or liver disease (creatinine \> 1.5 mg/dL, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2 × ULN, alkaline phosphatase \> 2 × ULN, or total bilirubin \[tBili\] \> 1.5 × ULN)~* Current immunosuppressive treatment or documented immunodeficiency~* Uncontrolled congestive heart failure~* Uncontrolled malignant disease~* Currently pregnant or breastfeeding~* known lactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo-Placebo (Type: PLACEBO_COMPARATOR): subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
- Investigational Drug A Empagliflozin (Type: ACTIVE_COMPARATOR): subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
- Investigational Drug B Anakinra (Type: ACTIVE_COMPARATOR): subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient

Based on this trial design, predict the completion outcome and termination type (if applicable).